Skip to search formSkip to main contentSkip to account menu

Alpharadin

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
The administration of a radionuclide in unsealed source whose radiation will destroy cells that have selectively accumulated… 
2012
2012
Abstract: Castration-resistant prostate cancer (CRPC) has a poor prognosis and remains a significant therapeutic challenge… 
2011
2011
Background Radium-223 (Alpharadin™) is a 1st-in-class alpha-pharmaceutical. It targets bone metastases (mets) with high-energy… 
2010
2010
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC A central theme in radiation therapy of cancer is… 
2009
2009
• The overall adverse event profile was consistent with that expected for patients undergoing treatment for advanced cancer with… 
2009
2009
Bayer and Algeta have entered into a deal to promote Algeta's novel alpha-ray emitting pharmaceutical based on radium-223 called…